Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TSE Research Core Facility Would Reduce Risks, Funding Hurdles - Rohwer

This article was originally published in The Gray Sheet

Executive Summary

HHS should help fund a "core facility" for transmissible spongiform encephalopathy (TSE) research that will facilitate development of a TSE assay, according to Robert Rohwer, PhD, TSE Resources, Inc., Columbia.

You may also be interested in...



Prion Research Should Focus On Diagnostics, Infrastructure – IoM

Development of effective diagnostics and additional research infrastructure in the field of prion science, as well as expanding basic research, are highlighted as priority areas for the Department of Defense National Prion Research Program in an interim IoM report

HHS Policy Move Means FDA Must Publish More Documentation To Support Rulemaking Decisions

To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel